GHRP-2

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Active malignancy: GH/IGF-1 elevation may accelerate tumor cell proliferation.
• History of pituitary tumor or pituitary adenoma: unpredictable response to GHS-R1a stimulation.
• Uncontrolled diabetes mellitus or severe insulin resistance: GH elevation worsens glycemic control.
• Diabetic ketoacidosis.
• Active or history of prolactinoma: GHRP-2 elevates prolactin via GHS-R1a activation on lactotrophs.
• Hypersensitivity or known allergy to GHRP-2 or excipients.
• Concurrent use with ipamorelin or GHRP-6: receptor competition at GHS-R1a; do not stack two GHRPs.
• Concurrent use with HGH 191aa: additive and redundant GH axis overstimulation.
• Concomitant high-dose glucocorticoid therapy: attenuates pituitary GH response and amplifies cortisol load from GHRP stimulation.
• Concomitant insulin therapy without adjustment: GH-mediated insulin resistance may destabilize glycemic control.
• High baseline cortisol or adrenal stress states: GHRP-2's cortisol-elevating effect adds further HPA axis load.
• Pregnancy: safety not established.
• Breastfeeding: safety not established.
• Pediatric use with closed growth plates.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Acute hunger and appetite stimulation: moderate; centrally mediated via ghrelin pathway NPY/AgRP activation; less intense than GHRP-6 but more than ipamorelin; begins within 20-30 minutes of injection.
• Mild cortisol elevation: transient, typically returns to baseline within 2-4 hours post-injection; approximately 40% less than GHRP-6 at equipotent doses; monitor in subjects with baseline cortisol concerns.
• Mild prolactin elevation: transient; similar pattern to cortisol response; lower than GHRP-6 and hexarelin.
• Head rush and transient facial flushing: acute vasodilation from GH pulse; resolves within 15-30 minutes.
• Water retention and peripheral edema: GH-mediated sodium and fluid retention; common in first 2-4 weeks.
• Joint stiffness: GH-related periarticular fluid accumulation.
• Tingling or numbness in extremities: paresthesia; GH-related fluid shifts.
• Vivid dreams: GH elevation during nocturnal sleep.
• Lethargy and mild fatigue post-injection: associated with the acute GH pulse.
• Headache: vasodilation-related; typically early in the protocol.
• Injection site irritation: redness, swelling, or pain at subcutaneous administration site.
• Mild transient hypoglycemia: possible when dosing fasted, particularly with GHRH analog co-administration.
• Insulin resistance: with extended high-dose protocols; GH elevation progressively reduces insulin sensitivity; monitor fasting glucose.
• Decreased efficacy of corticosteroid therapy: GHRP-2 can blunt glucocorticoid response.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• PubMed search: GHRP-2